ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1499	National Cancer Institute	Html	en	Paranasal Sinus and Nasal Cavity Cancer Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of paranasal sinus and nasal cavity cancer.	hemiparanasal sinus 0.501642 cure rates 0.493854 positive nodes 0.488668 standard treatment schedules 0.549584 Nodal involvement 0.497639 cancer deaths 0.490757 small percentage 0.485324 paranasal sinuses 0.76526 operable tumors 0.521562 PDQ cancer information 0.674275 (es). 0.507032 T1 mucosal carcinomas 0.579667 neck radiation therapy 0.604078 cancer information summary 0.645943 frequent type 0.494315 high doses 0.481624 Squamous cell carcinoma 0.582109 breast cancer prevention 0.543533 direct extension 0.48751 malignant degeneration 0.512598 advanced carcinomas 0.493525 ethmoid sinuses 0.558752 NCI’s PDQ 0.512104 NCI PDQ cancer 0.582736 paranasal sinus cancers 0.63814	radical surgery 0.487234 frontal sinuses 0.560784 radiation therapy 0.931486 low-grade benign tumor 0.581394 maxillary sinus 0.511122 locoregional recurrence accounts 0.563108 nasal vestibule 0.506572 Lymph nodes 0.492664 vital areas 0.483188 distant metastases 0.516432 bony confines 0.499241 malignant tumor 0.600994 PDQ documents 0.510902 early tumors 0.514544 radical radiation therapy 0.591316 advanced disease 0.493565 nasal cavity 0.593061 treatment volume 0.481814 local disease 0.484616 tumors 0.539577 stage III tumors 0.513203 neck cancer 0.495811 postoperative radiation therapy 0.591777 adjacent structures. 0.488857	CLICK HERE
1561	National Cancer Institute	Html	en	Hairy Cell Leukemia Treatment (PDQ®)–Patient Version	Expert-reviewed information summary about the treatment of hairy cell leukemia.	red blood cells 0.288652 cancer treatment 0.275128 following PDQ summaries 0.252637 PDQ cancer information 0.3118 clinical trial search 0.280542 white blood cells 0.33408 clinical trials 0.546221 mature blood cells 0.288256 Natural killer cells 0.259899 bone marrow cell 0.248193 cancer information summary 0.285589 clinical trial 0.391443 patients 0.269231 blood cells 0.357276 earlier clinical trials 0.248664 Biologic therapy 0.261621 refractory hairy cell 0.259547 treatment clinical trial 0.258654 PDQ Adult Treatment 0.254235 Cell Leukemia Treatment 0.279873 NCI PDQ cancer 0.262149 Treatment Editorial Board 0.264015 treatment 0.372653 myeloid stem cell 0.267967	blood stem cell 0.256899 progressive hairy cell 0.304412 new cancer treatments 0.249482 NCI-supported cancer 0.251402 cancer cells 0.341635 lymphoid stem cell 0.268394 laboratory test 0.252149 Cancer Information Service 0.24796 specific cancer cells 0.268675 treatment clinical trials 0.277379 blood stem cells 0.287064 National Cancer Institute 0.286081 normal cells 0.252914 new treatment 0.277346 hairy cell leukemia 0.902024 bone marrow 0.339709 healthy blood cells 0.262175 untreated hairy cell 0.280676 cancer clinical trials 0.292375 cancer information summaries 0.250228 comprehensive cancer information 0.249864 cancer 0.442493 standard treatment 0.257771 leukemia cells 0.29846	CLICK HERE
1599	National Cancer Institute	Html	en	Selected Vegetables/Sun's Soup (PDQ®)–Health Professional Version	Expert-reviewed information summary about the use of selected vegetables/Sun's soup as a treatment for people with cancer. Note: The information in this summary is no longer being updated and is provided for reference purposes only.	General Information section 0.439986 phase I/II 0.372901 soup 0.641588 eligible patients 0.381172 United States 0.398891 Human/Clinical Studies section 0.504014 standard laboratory chow 0.498456 advanced non-small cell 0.617549 toxicity arm 0.381025 control group 0.47167 Sun’s Soup 0.39938 cell lung cancer. 0.443882 Soup treatment group. 0.419226 fed standard laboratory 0.408383 conventional therapy 0.380328 Vegetables/Sun’s Soup 0.633353 dietary supplements 0.390642 tumor growth 0.410892 percent body-weight loss 0.372171 lymph node metastasis 0.373015 average KPS score 0.387592 barbat skullcap 0.397578 cancer information summary 0.38735 patent document 0.416332	clinical trial 0.401308 mung bean 0.484404 barbata D. Don 0.434127 best supportive care 0.383219 shiitake mushroom 0.46504 patients 0.656235 primary tumor 0.381698 Selected Vegetables/Sun 0.926979 Scutellaria barbata D. 0.437829 KPS score 0.444385 non-small cell lung 0.820617 survival arm 0.438189 Phaseolus radiatus L. 0.435744 nonconsecutive case series 0.385568 median survival time 0.500228 cell lung cancer 0.65934 study entry 0.475867 Soup treatment group 0.54526 radiation therapy 0.522928 Hedyotis diffusa Willd. 0.437904 mice fed standard 0.407302 Soup dietary supplement 0.400111 I/II clinical trial 0.398282	CLICK HERE
1617	National Cancer Institute	Html	en	Chronic Myeloproliferative Neoplasms Treatment (PDQ®)–Patient Version	Expert-reviewed information summary about the treatment of chronic myeloproliferative neoplasms.	red blood cells 0.746761 chronic idiopathic myelofibrosis 0.40092 cancer treatment 0.416363 primary myelofibrosis 0.53957 PDQ cancer information 0.430215 bone marrow aspiration 0.385705 clinical trial search 0.421224 white blood cells 0.676519 chronic eosinophilic leukemia 0.451961 blood cells increases 0.444984 clinical trials 0.768861 chronic neutrophilic leukemia 0.40279 mature blood cells 0.434847 fewer blood cells 0.406923 cancer information summary 0.401424 clinical trial 0.500574 early signs 0.377313 patients 0.431687 blood cells 0.902472 blood vessels 0.37721 chronic myelogenous leukemia 0.406738 Treatment Editorial Board 0.377482 essential thrombocythemia 0.420345 treatment 0.55278 stored stem cells 0.37624	immature blood cells 0.399031 blood stem cell 0.37725 cancer cells 0.408902 -fighting blood cells 0.405086 lymphoid stem cell 0.374191 specific cancer cells 0.392312 chronic myeloproliferative neoplasms 0.69658 signs 0.38226 polycythemia vera 0.418683 patient 0.388228 treatment clinical trials 0.396123 blood stem cells 0.497004 National Cancer Institute 0.457233 routine blood test 0.45249 new treatment 0.393316 white blood cell 0.399685 extra blood cells 0.469808 bone marrow 0.605562 PDQ summary 0.382577 cancer clinical trials 0.425229 blood clots 0.392843 cancer 0.517448 information 0.439199 Myelogenous Leukemia Treatment 0.387746	CLICK HERE
1715	National Cancer Institute	Html	en	Tests to Detect Colorectal Cancer and Polyps	A fact sheet that discusses the advantages and disadvantages of several colorectal cancer screening tests.	standard colonoscopy 0.642704 average risk 0.571434 sigmoidoscopy screening 0.568313 entire colon 0.614214 colorectal polyps 0.605561 abnormal growths 0.57234 colon problems 0.570159 Occult Blood Test 0.556564 early-stage colorectal cancer 0.600935 occult blood tests 0.564372 thorough cleansing 0.581775 asymptomatic colorectal cancer 0.60263 flexible lighted tube 0.561607 colorectal cancer screening 0.734621 flexible sigmoidoscopy screening 0.562785 small polyps 0.567222 digital rectal examination 0.560544 polyps 0.617192 colorectal cancer 0.956004 test 0.736074 new colorectal cancer 0.625336 guaiac FOBT 0.612613 single-specimen guaiac fobt 0.570386 inflammatory bowel disease 0.568257 ) colonoscopy. 0.566733	colon cancer incidence 0.618181 acceptable screening tests 0.563922 fecal occult blood 0.636365 colorectal cancers 0.601521 rectum 0.592026 colon tissue 0.560628 lower colon 0.576523 colon cancer mortality 0.592993 United States 0.573668 Additional procedures 0.566333 colonoscopy screening methods 0.603294 False-positive test results 0.579985 stool sample 0.563739 colorectal cancer incidence 0.613064 colon cancer 0.621651 fecal immunochemical test 0.563508 stool dna test 0.61197 people 0.593294 virtual colonoscopy 0.697133 cancer screening tests 0.581698 family history 0.558032 sigmoid colon 0.589237 colon 0.791161 et al 0.626521	CLICK HERE
1825	National Cancer Institute	Html	es	Tratamiento del cáncer de hígado infantil (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento cáncer de hígado infantil.	liver tumors 0.936797 Pediatric Oncology 0.824708 PRETEXT III 0.10879 Aronson DC 0.0851201 results from 0.266716 Paediatric Oncology 0.0823629 international pediatric liver 0.110029 Tumor Study Group 0.204309 standard-risk hepatoblastoma 0.125193 childhood liver tumors 0.0905382 Study Group 0.298822 Maibach R 0.0922692 hepatocellular carcinoma 0.861587 International Society 0.42048 IV hepatoblastoma 0.218263 Krailo MD 0.0915991 cog liver tumors 0.124853 Children's Oncology Group 0.248758 Estados Unidos 0.091099 hepatoblastoma with 0.740659 pediatric liver tumors 0.222622 hepatoblastoma after chemotherapy 0.124744 Pediatric Oncology Liver 0.123326 childhood hepatoblastoma 0.552956 with hepatoblastoma 0.638805	Perilongo G 0.171974 PRETEXT IV 0.0802866 grupos pretext 0.174753 Group intergroup study 0.0861929 Pediatr Blood Cancer 0.319797 Oncology Group study 0.119848 childhood liver 0.102417 Japanese Study Group 0.0968813 report from 0.211803 Childrens Cancer Study 0.0958008 quimioterapia preoperatoria 0.196007 Hepatoblastoma presenting with 0.134427 Liver Tumor Study 0.217304 Pediatr Surg 0.270609 Clin Oncol 0.979661 Hepatoblastoma metastatic 0.11507 Otte JB 0.0939222 Children's Cancer Group 0.202883 Shafford E 0.259892 prospective study 0.154606 Oncology Liver Tumor 0.132492 pediatric oncology group 0.588258 oncology group 0.803949 Cancer Study Group 0.108904	CLICK HERE
1911	National Cancer Institute	Html	es	Tratamiento del cáncer de células renales (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca del tratamiento del cáncer de células renales.	siguientes procedimientos 0.302667 mal uso 0.302989 siguientes aspectos 0.301319 estadio ii 0.309628 túbulos renales 0.304796 pequeños trozos 0.300679 siguientes tipos 0.302146 Renal Cell 0.303601 rayos x 0.302568 sistema urinario masculino 0.3018 enlace drugs approved 0.306606 riñón sano donado 0.303031 National Cancer Institute 0.300453 siguientes riesgos 0.300391 realidad células 0.303887	pelvis renal 0.306725 Instituto Nacional 0.301826 PDQ Tratamiento 0.304405 Physician Data Query 0.301827 nefrectomía radical 0.310748 pequeña incisión 0.300747 tumor mide 0.303146 von hippel-lindau 0.30106 vejiga almacena 0.301249 pequeños túbulos 0.301281 siguientes enlaces 0.300545 células renales 0.988263 riesgo cáncer 0.31289 siguientes pruebas 0.301322 vasos sanguíneos 0.317262	CLICK HERE
3440	National Cancer Institute	Html	es	Exámenes de detección del neuroblastoma (PDQ®)–Versión para pacientes	Sumario de información revisada por expertos sobre pruebas que se usan para detectar el neuroblastoma.	Visuals Online 0.563675 PDQ Exámenes 0.77452 Physician Data Query 0.971175 ecografía fetal 0.642315 prevención revisa 0.581226 graves riesgos 0.622769	presente síntomas 0.605798 información ayuda 0.590632 cuáles tipos 0.60865 National Cancer Institute 0.613572 siguientes riesgos 0.582879 Instituto Nacional 0.71673	CLICK HERE
4337	National Cancer Institute	Html	en	Appetite Loss and Cancer Treatment	Cancer treatments may lower your appetite. Side effects such as nausea, fatigue, or mouth sores can also making eating difficult. Learn how to eat well to avoid losing weight or becoming dehydrated, so you stay strong during treatment.	Care PDQ® summary 0.905921 questions 0.493671 liquids 0.644562 dietitian 0.466542 short walk 0.691875 health care team 0.956003 professional version 0.683094 variety 0.451735 causes 0.450224 nurse 0.455725 Prepare 0.451462 dehydration 0.472596 throat problems 0.73358 drink choices 0.682925 vomiting 0.475861 food tastes 0.745638 Cancer treatments 0.729931 cancer patients 0.671489 supplemental nutrition drinks 0.886258 weight 0.457616 large meals 0.701392 plenty 0.541422	calories 0.468062 list 0.493655 eating 0.456684 steps 0.457353 people 0.451814 dangerous condition 0.706738 small meals 0.702125 way 0.460708 nausea 0.479468 nutritional problems 0.667746 doctor 0.457447 symptoms 0.451468 supplements 0.451833 Cancer-related fatigue 0.794241 effects 0.460377 mouth 0.464482 vitamins 0.459091 NCI 0.456663 high-nutrient foods 0.702331 appetite 0.964964 information 0.45027 nutrient-dense foods 0.715035	CLICK HERE
16567	National Cancer Institute	Html	en	Pembrolizumab Improves Survival for Some Patients with Advanced Non-Small Cell Lung Cancer	A summary of clinical trial results showing that pembrolizumab improved progression-free and overall survival for patients with advanced non-small cell lung cancer.	platinum-based chemotherapy 0.628936 PD-L1 positive tumors 0.620887 advanced non-small cell 0.629259 PD-L1 expression 0.628117 1-year overall survival 0.61848 higher progression-free survival 0.617259 chemotherapy 0.698592 time patients 0.588415 chemotherapy group 0.668963 immune-mediated adverse events 0.635601 Dana-Farber Cancer Institute 0.607312 lung cancer 0.570765 biomarker. Earlier trials 0.611797 PD-L1 IHC 22C3 0.643265 immune response 0.572023 PD-L1 protein present 0.63991 overall survival 0.629887 immune-mediated deaths 0.578857 National Cancer Institute 0.604313 tumor cells 0.913581 randomized phase 0.574689 median progression-free survival 0.633329 PD-L1-expressing tumor cells 0.661448 immune therapy 0.577956	immune-mediated events 0.578589 progression-free survival 0.757999 pembrolizumab group 0.672943 platinum-based doublet chemotherapy 0.672126 standard chemotherapy 0.609699 phase III CheckMate 0.569846 patients 0.63251 trial results 0.620704 previously treated patients 0.61738 immune cells 0.61252 adverse events 0.670445 Dr. Malik 0.709776 earlier phase trial 0.627214 metastatic NSCLC 0.599852 Bruce E. Johnson 0.59961 survival advantage 0.568599 untreated advanced NSCLC 0.642891 New England Journal 0.615224 severe skin reactions 0.605442 checkpoint inhibitor pembrolizumab 0.658193 phase III trial 0.569107 Pembrolizumab blocks PD-1 0.629649 Shakun Malik 0.582607	CLICK HERE